Peer reviewed clinical letter
Vol. 145 No. 3738 (2015)
Moraxella osloensis, an emerging pathogen of endocarditis in immunocompromised patients?
- Jean-Charles Gagnard
- Nadia Hidri
- Antoine Grillon
- Laurence Jesel
- Eric Denes
-
Cite this as:
-
Swiss Med Wkly. 2015;145:w14185
-
Published
-
06.09.2015
Summary
We report two cases of endocarditis due to Moraxella osloensis. Only one previous case of such infection has been described. These infections occurred in immunocompromised patients (B-cell chronic lymphocytic leukaemia and kidney graft associated with Hodgkin’s disease) and both patients had a favourable outcome with a complete cure of their infectious endocarditis. This bacterium could be an emerging pathogen revealed by MALDI-TOF. Indeed, its characterisation within the Moraxella group by use of biochemistry-based methods is difficult. Moreover, this strain could be particularly involved in immunocompromised patients.
References
- Murphy T. Moraxella (Branhamella) catarrhalis and other Gram-negative Cocci. Principles and Practice of Infectious Diseases. 2005. p. 2529–36.
- Baumann P, Doudoroff M, Stanier RY. Study of the Moraxella group. I. Genus Moraxella and the Neisseria catarrhalis group. J Bacteriol. 1968;95(1):58–73.
- Stryker TD, Stone WJ, Savage AM. Renal failure secondary to Moraxella osloensis endocarditis. Johns Hopkins Med J. 1982;150(6):217–9.
- Bövre K, Henriksen SD. A new Moraxella species, Moraxella osloensis, and a nonliquefaciens, revised description of Moraxella. Intern J Syst Bacteriol. 1967;17:127–35.
- Dien Bard J, Lewinski M, Summanen PH, Deville JG. Sepsis with prolonged hypotension due to Moraxella osloensis in a non-immunocompromised child. J Med Microbiol. 2011;60:138–41.
- Han XY, Tarrand JJ. Moraxella osloensis blood and catheter infections during anticancer chemotherapy: clinical and microbiologic studies of 10 cases. Am J Clin Pathol. 2004;121(4):581–7.